

DAFTAR PUSTAKA

- Aryandono, T., Epidemiologi, Faktor Resiko, Genetik dan Skrining Kanker Payudara. Diunduh dari: www.4shared.com/.../Epidemiologi_faktor_resiko_gen.html. Update terakhir: 25 juli 2008.
- American Cancer Society.: Cancer Facts and Figures 2011. Available from: www.cancer.gov. . Last accessed July 27, 2011.
- American Cancer Society. 2010. Breast Cancer. Available from: www.cancer.org. Accessed on: December 15, 2011. Last update on: Juny 3, 2012.
- Azamris. 2006. Analisis Faktor Risiko pada Pasien Kanker Payudara di Rumah Sakit Dr. M. Djamil Padang. Cermin Dunia Kedokteran No. 152.
- Barcenas, C.H., Wells, J., Chong, D. 2010. Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry. *Clin Breast Cancer*. 10(1):59-63.
- Brashers, VL. 2007. Aplikasi Klinis Patofisiologi: Pemeriksaan & Manajemen. Edisi 2. Jakarta: EGC: 127-130.
- Brown, N.S., Bicknell, R. 2011. Hypoxia and oxidative stress in breast cancer Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res*. 3:323–327.
- Cancer Research UK. Breast Cancer-UK. Available from: <http://info.cancerresearchuk.org/>. Last update: May 2009.
- Carey, L.A., Perou, C.M., Livasy, C.H. 2006. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. *JAMA*. 295: 2492-2502
- Casciato, D.A. 2004. *Manual of Clinical Oncology*. 5th ed. Lippincott Williams & Wilkins. USA. 201.
- Dahlui, M., Ramli, S., Bulgiba, A. 2011. Breast Cancer Prevention and Control Programs in Malaysia. *Asian Pacific J Cancer Prev*. 12: 1631-1634
- Davey, P. 2005. Kanker Payudara. *At a Glance Medicine*. Erlangga. Jakarta. 173-174.

- Decock, J., Paridaens, R., Ye, S. 2008. Genetic Polymorphisms of Matrix Metalloproteinases in Lung, Breast and Colorectal Cancer. *Clin Genet.* 73:197-221.
- Desen, W., Japaries, W. 2011. Tumor Daerah Toraks. *Buku Ajar Onkologi Klinik.* Edisi 2. Balai Penerbit FKUI. Jakarta.
- Economist Intelligence Unit. 2009. Breakaway: The global burden of cancer-challenges and opportunities. Available from: <http://livestrongblog.org/>.
- Eroschenko, V.P. 2003. Kelenjar Mammae. *Atlas Histologi di Fiore dengan Korelasi Fungsional.* Edisi 9. EGC. Jakarta. 327-329
- Faiz, O., Moffat D. 2004. Drainase Vena dan Limfatik Ekstremitas Atas dan Payudara. *At a Glance Series Anatomi.* Erlangga. Jakarta. 64-65
- Fan, SQ., Wei, QY., Li, MR., Zhang, LQ. 2003. Expression and clinical significance of MMP-2, MMP-9, TIMP-1, and TIMP-2 in breast carcinoma. *Ai Zheng.* 22(9):968-73
- Garbett, E.A., Reed, M. W., Stephenson, T.J., Brown, N.J. 2000. Proteolysis in human breast cancer. *Mol Pathol.* 53(2): 99–106.
- Goodsell, D.S. 1999. The Molecular Perspective: Matrix metalloproteinase 2. *The Oncologist.* 4960; 509-11.
- Greene, F.L., Page, D.L., Fleming, I.D., et. al. 2002. *AJCC Cancer Staging Manual.* Sixth Ed. Springer. Philadelphia. 225-230.
- Hardjoeno, dkk. 2003. Tumor Marker. *Interpretasi Hasil Tes Laboratorium Diagnostik.* Lembaga Penerbitan Universitas Hasanuddin. Makassar. 421-423.
- Heffner, LJ., Schust, DJ. 2005. *At a Glance: Sistem Reproduksi.* Edisi Kedua. Jakarta: Erlangga Medical Series.
- Hemati, S., Sadeghi, M., Motovali-Bashi, M., et al. 2010. Higher plasma MMP-9 level in breast cancer patients with MMP-9 promoter T allele. *J. Biol. Res.-Thessalon.* 13: 113 – 118.
- Hukom, R.A., 2003. Risiko Kanker Payudara Ditinjau dari Segi Epidemiologi. *Penatalaksanaan Kanker Payudara Terkini.* (Tim Penanggulangan & Pelayanan Kanker Payudara Terpadu Paripurna R.S. Kanker Dharmais). Jakarta: Pustaka Populer Obor: 1-9

- Hunt, K.K., Rob, G.L., Strom, E.A., et.al. 2008. *Breast Cancer*. Second Edition. Springer. Philadelphia. P: 1-18.
- Jakowlew, S.B. 2008. *Transforming Growth Faktor- β in Cancer Terapy: Basic and Clinical Biology*. Humana Press. New Jersey.
- Jemal, A., Bray, F., Melissa, M., et al. 2011. Global Cancer Statistics. *CA CANCER J CLIN*. 61:69–90.
- Jordan, M. 2003. *Managing Breast Cancer Risk*. BC Decker Inc. New York. 3-15.
- Jung, K., Laube, C., Lein, M., et.al. 1998. Kind of Sample as Preamalytical Determinant of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 in Blood. *ClinChem*. 44 (5): 1060-1062
- Kersten, K. 2011. Predicting Breast Cancer Metastasis; Formation of the Pre-metastatic Niche. Available from: <http://igitur-archive.library.uu.nl/>. Access: Oct 30, 2011.
- Kim, B. 1995. Cigarette Smoking and Breast. *BMJ*. 9: 1431-1433.
- Kim, K., Kim, J.W. 2007. Tumor Metastasis: matriks metalloproteinase-9 (MMP-9). *BioWave*. 9 (1): 1-15.
- Kresno, S.B. 2011. Ilmu Dasar Onkologi. Badan Penerbit FKUI. Jakarta
- Kumar, V., Cotran, R.S., Robbins, S.L. 2007. *Buku Ajar Patologi Robbins*. Edisi 7. EGC. Jakarta. 199-215.
- Kurnia, A., Ramli, H.M., Albar, Z.A., dkk. 2008. Prediksi, Intervensi dan Prevalensi Kanker Payudara. *Kanker Kepala, Leher, Payudara dan Rekonstruksi*. Balai Penerbit FKUI. Jakarta,. Hal: 216-229.
- Lee, M.H., Murphy, G. 2004. Matrix Metalloproteinases at a Glance. *Journal of Cell Sciense*. 117: 4015-6.
- Lippman, M.E., dickson R.B. 1998. *Breast Cancer: Cellular and Molecular Biology*. Kluwer Academic Publisers. Boston. 1-9.
- Mayer, M. 2003. Treatment and Outcomes for High-risk and Metastatic Breast Cancer in California: An Inquiry into Disparities and Research Needs.

- McGowan, P.M., Duffy, M.J. 2008. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. *Ann Oncol.* 19 (9): 1566-1572.
- Menghadam, A.F., Stieber, P. 1996. General Criteria for the Use of Tumour Markers in Sensible Use of Tumour Markers. Roche. Switzerland. 11-31
- Milošević, Z., Gajić-Dobrosavljević, M., Stevanović, J. 2006. Diagnostic Imaging Methods in Metastatic Disease. *Archive of oncology.* 14 suppl 1:73-4.
- Molina, R., Barak, V., van Dalen, A. 2005. Tumor Markers in Breast Cancer - European Group on Tumor Markers Recommendations. *Tumor Biol* ;26:281–293
- Motovali-Bashi, M., Sadeghi, M., Hemati, S., 2010. Serum MMP-9 Level Associated with Initiation and Progression Steps of Breast Cancer in the Iranian Population. *Reproductive Sciences.* 17: 585-589.
- National Cancer Institute. 2009. Available from: www.cancer.gov.
- O-charoenrat, P., Rhys-Evans, P.H., Eccles, S.A. 2001. Expression of Matrix Metalloproteinases and their inhibitors Correlates with Invasion and Metastasis in Squamous Cell Carcinoma of the Head and Neck. *Arch Otolaryngol Head neck Surg.* 127: 813-20.
- Provatopoulou, X., Gounaris, A., Kalogera, E. 2009. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. *BMC Cancer.* 9:390.
- Quaia, E., D'Onofrio, M., Palumbo, A., et.al. 2006. Comparison of Contrast-Enhanced Ultrasonography Versus Baseline Ultrasound and Contrast-Enhanced Computed Tomography in Metastatic Disease Of The Liver: Diagnostic Performance And Confidence. *Eur Radiol.* 16:1599-609.
- Quaranta, M., Daniele, A., Coviello, M., et al. 2007. MMP-2, MMP-9, VEGF and CA 15.3 in Breast Cancer. *Anticancer Res.* 27: 3593-3600

- Ranunculo, S.M., Armanasco, E., Cresta, C., et. Al. 2003. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. *IJC*. 106: 745-751.
- Rasjidi, I. 2010. Kanker Payudara. *100 Question & Answer Kanker pada Wanita*. PT Gramedia. Jakarta. 17-35.
- Richards, C.D., Shoyab, M., Brown, T.J., Gauldie, J. 1993. Selective regulation of Metalloproteinase Inhibitor (TIMP-1) by Oncostatin M in Fibroblast in Culture. *The Journal of Immunology*. 150(12): 5596-603.
- Rundhaug, J.E. 2003. Matrix metalloproteinase, Angiogenesis and Cancer. *Clinicancerres*. 9: 551-554.
- Sahani, DV., Kalva, SP. 2004. Imaging the Liver. *The Oncologist*. 9: 385-397.
- Schwartz, S.I. 2000. *Intisari Prinsip-prinsip Ilmu Bedah*. EGC. Jakarta. 227-230.
- Schoenfeld, E.R., O'Leary, E.S., Henderson, K. 2003. Electromagnetic Fields and Breast Cancer on Long Island: A Case-Control Study. *Am J Epidemiol*. 158:47–58.
- Scottish Intercollegiate Guidelines Network. 2005. Management of Breast Cancer in Women: A National Clinical Guidelines. www.sign.ac.uk. Accessed September 27, 2011.
- Sevianty, S. 2011. Analisis Nilai 5-Hydroxyindoleacetic Acid (5-HIAA) pada Penderita Carcinoma Mammae.
- Somiari, S.B., Somiari, R.I., Heckman, C.M. 2006. Circulating MMP2 and MMP9 in breast cancer—Potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. *IJC*. 119: 1403-1411.
- Stebbing, J and Ngan, S. 2010. Breast cancer (metastatic). <http://clinicalevidence.bmj.com>. Last update: September 8, 2010. Accessed: January 3, 2012.
- Stephen, S., Legare, R.D. 2002. Risk Factor for Breast Cancer. *Obstetry and Gynecology Clinics*. Saunders Company. Philadelphia.

- Stuelten, C.H., Byfield, S.D., Arany, P.R., et.al. 2005. Breast Cancer Cells Induce Stromal Fibroblast to Express MMP-9 via Secretion of TNF- α and TGF- β . *Journal of Cell Science*. 118: 2143-2153.
- Subarkah, A., 2008. Kanker Payudara. Diunduh dari: www.klinikindonesia.com. Diakses 9 Agustus 2011.
- Swain, S.M. 2006. *Inflammatory Breast Cancer*. IOS Press. 25-30.
- Szmitko, P.E., Wang, C.H., Weisel, R.D., et al. 2003. Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation. Part II. *Circulation*. 108: 2041-2048.
- Thraillkill, K., Cockrell, G., Simpson, P. 2006. Physiological Matrix Metalloproteinase (MMP) Concentration: Comparison of Serum and Plasma Specimens. *Clin Chem Lab Med*. 44(4): 503-504.
- Valentina, L. 2007. *Aplikasi Klinis Patofisiologi: Pemeriksaan dan Manajemen*. EGC. Jakarta. 127-132
- Vogl, M., Muller, MM. 2002. Tumor Markers: review and Clinical Applications. *IFCC*, 5-30
- Whatling, C., McPheat, W. And Hurt-Camejo, E. 2004. Matrix Management Assigning Different Roles for MMP-2 and MMP-9 in Vascular Remodelling. *Arterioscler Thromb Vasc Biol*. 24: 10-11.
- World Health Organization. World Cancer Day 2011. Available from: www.who.int. Last update: 4 February 2011-08-12.
- Wu, Z.S., Wu, Q., Yang, J.H. 2008. Prognostic Significance Of MMP-9 And TIMP-1 Serum And Tissue Expression In Breast Cancer. *IJC*. 122: 2050-2056.

Lampiran 2. Formulir Persetujuan Mengikuti Penelitian

SURAT PERSETUJUAN

Setelah mendapat penjelasan mengenai maksud, tujuan dan manfaat penelitian dengan judul: **“Analisis Kadar *Matrix Metalloproteinase-9 (MMP-9)* pada Penderita *Carcinoma mammae*”** ; maka saya yang bertanda tangan di bawah ini:

Nama :

Umur :

Alamat :

Menyetujui dan bersedia ikut serta dalam penelitian ini. Bila suatu waktu saya merasa dirugikan dalam bentuk apapun, saya berhak menghentikan peran serta saya dalam penelitian ini kapan saja dengan memberitahukan kepada peneliti.

Demikian pernyataan persetujuan ini saya buat dalam keadaan sadar dan tanpa paksaan dari pihak manapun.

Makassar,2011

Peneliti

Peserta Penelitian

(dr. Wildana)

()

Lampiran 3

DATA DASAR PENELITIAN

NO	NAMA	UMUR (Tahun)	STADIUM (TNM)	KADAR MMP-9 (ng/mL)	KATEGORI STADIUM	DIAGNOSIS HISTOPATOLOGI
1	ADB	36	II B	383,219	STADIUM DINI	Adenocarcinoma mammae
2	BS	38	I	503,534	STADIUM DINI	Apokrin Cell Carcinoma
3	N	38	II B	0,000	STADIUM DINI	Ca. Mamma
4	AM	41	II A	283,265	STADIUM DINI	Invasive ductal carcinoma
5	H	45	II A	453,557	STADIUM DINI	Invasive ductal carcinoma
6	AR	42	II A	527,597	STADIUM DINI	Adenocarcinoma mammae
7	ND	46	II B	481,322	STADIUM DINI	Fibrokystic disease
8	J	41	II A	403,580	STADIUM DINI	Adenocarcinoma mammae
9	HS	42	I	1018,112	STADIUM DINI	Invasive ductal carcinoma
10	S	43	II A	560,915	STADIUM DINI	Invasive ductal carcinoma
11	NS	52	II B	644,210	STADIUM DINI	Adenocarcinoma mammae
12	NJ	54	II B	714,548	STADIUM DINI	Ca. Mamma
13	M	42	III B	932,966	STADIUM LANJUT LOKAL	Adenocarcinoma mammae
14	IR	42	III A	538,703	STADIUM LANJUT LOKAL	Invasive ductal carcinoma
15	HB	38	III B	1280,954	STADIUM LANJUT LOKAL	Ca. Mamma
16	MB	33	III C	246,245	STADIUM LANJUT LOKAL	Adenocarcinoma mammae
17	HW	43	III B	462,812	STADIUM LANJUT LOKAL	Adenocarcinoma mammae
18	HM	46	III B	609,041	STADIUM LANJUT LOKAL	Invasif ductal carcinoma
19	SN	33	III B	2400,809	STADIUM LANJUT LOKAL	Ca Mammae
20	HN	51	III B	1193,957	STADIUM LANJUT LOKAL	Adenocarcinoma mammae
21	NH	41	III B	968,135	STADIUM LANJUT LOKAL	Invasif ductal carcinoma
22	RT	42	III B	560,915	STADIUM LANJUT LOKAL	Adenocarcinoma mammae
23	RS	33	III A	932,966	STADIUM LANJUT LOKAL	Adenocarcinoma mammae
24	HE	43	III B	1164,341	STADIUM LANJUT LOKAL	Invasif ductal carcinoma
25	C	58	III B	1210,616	STADIUM LANJUT LOKAL	Adenocarcinoma
26	RD	49	III B	1108,811	STADIUM LANJUT LOKAL	Ca. Mammae
27	SG	41	III B	932,966	STADIUM LANJUT LOKAL	Invasif ductal carcinoma
28	IS	41	III B	831,161	STADIUM LANJUT LOKAL	Ca. Mammae
29	TD	36	III B	818,204	STADIUM LANJUT LOKAL	Invasive ductal carcinoma
30	EB	42	III B	969,986	STADIUM LANJUT LOKAL	Adenocarcinoma
31	AT	36	III B	605,339	STADIUM LANJUT LOKAL	Adenocarcinoma
32	SR	47	III B	266,606	STADIUM LANJUT LOKAL	Adenocarcinoma
33	NY	39	III C	1530,839	STADIUM LANJUT LOKAL	Invasive ductal ca
34	MR	48	III B	671,975	STADIUM LANJUT LOKAL	Adenocarcinoma

35	ADL	34	III B	862,628	STADIUM LANJUT LOKAL	Adenocarsinoma
36	HTJ	67	III C	975,539	STADIUM LANJUT LOKAL	Invasive ductal carcinoma
37	EV	32	III B	1003,304	STADIUM LANJUT LOKAL	Adenocarsinoma
38	ISY	55	III B	403,580	STADIUM LANJUT LOKAL	ca. Mammae
39	SE	49	III C	1284,656	STADIUM LANJUT LOKAL	Invasive ductal carcinoma
40	GW	48	III B	159,248	STADIUM LANJUT LOKAL	Adenocarcinoma
41	NI	41	III A	1342,037	STADIUM LANJUT LOKAL	Adenocarcinoma
42	NO	50	III B	420,239	STADIUM LANJUT LOKAL	Ca. Mammae
43	HLM	68	III B	349,901	STADIUM LANJUT LOKAL	Invasive ductal carcinoma
44	SNT	34	III C	577,574	STADIUM LANJUT LOKAL	Adenocarcinoma
45	ER	34	IV	736,760	STADIUM METASTASIS	Invasif ductal carcinoma
46	ELS	46	IV	448,004	STADIUM METASTASIS	Invasif ductal carcinoma
47	HAE	48	IV	274,010	STADIUM METASTASIS	Ca. Mammae
48	AU	31	IV	916,307	STADIUM METASTASIS	Ca. Mammae
49	HAS	34	IV	631,253	STADIUM METASTASIS	Ca. Mammae bilateral
50	HSN	36	IV	522,044	STADIUM METASTASIS	Invasive ductal carcinoma
51	KAM	66	IV	831,161	STADIUM METASTASIS	Ca. Mammae
52	JHE	53	IV	1151,384	STADIUM METASTASIS	Invasive ductal carcinoma
53	JHU	64	IV	224,033	STADIUM METASTASIS	Invasive ductal carcinoma
54	KAS	48	IV	405,431	STADIUM METASTASIS	Adenocarcinoma
55	MSY	39	IV	1236,530	STADIUM METASTASIS	Invasive ductal carcinoma
56	HNW	31	IV	1181,000	STADIUM METASTASIS	Ca. Mammae

Lampiran 4

**Sensitivitas, Spesifisitas, Nilai Prediksi Positif dan Nilai Prediksi
Negatif dari Masing-masing *Cut off Point***

MMP-9 (ng/mL)	Sensitivitas (%)	Spesifisitas (%)	Nilai Prediksi Positif (%)	Nilai Prediksi Negatif (%)
79,62	100,0	8,3	80,0	100,0
191,64	100,0	8,3	80,0	100,0
235,14	95,0	8,3	79,2	33,3
256,42	93,0	8,3	78,8	25,0
270,3	90,0	8,3	78,4	20,0
278,63	87,0	8,3	78,0	16,6
316,58	88,0	17,0	79,6	28,6
366,56	86,0	17,0	79,2	25,0
393,39	86,0	25,0	80,8	33,3
404,5	84,0	33,3	82,2	36,4
412,83	81,8	33,3	81,8	33,3
434,12	79,5	33,3	81,4	30,8
450,78	77,3	33,3	80,9	28,6
458,18	77,3	41,7	82,9	33,3
472,06	75,0	41,7	82,5	31,3
492,43	75,0	50,0	84,6	35,3
512,79	75,0	58,3	86,8	38,9
524,82	72,7	58,3	86,5	36,9
533,15	72,7	66,7	88,9	40,0
549,8	70,5	66,7	88,6	38,1
569,24	68,2	75,0	90,9	39,1
591,45	65,9	75,0	90,6	37,5
607,19	63,6	75,0	90,3	36,0
620,14	61,4	75,0	90,0	34,6
637,73	59,1	75,0	89,6	33,3
658,09	59,1	83,3	92,8	35,7
693,26	56,8	83,3	92,6	34,5
725,65	56,8	91,7	96,1	36,7
777,48	54,5	91,7	96,0	35,5
824,68	52,3	91,7	95,8	34,3
846,89	47,7	91,7	95,5	32,3
889,46	45,5	91,7	95,2	31,4

Lanjutan Lampiran 4

924,63	43,2	91,7	95,0	30,5
950,55	36,4	91,7	94,1	28,2
969,06	34,1	91,7	93,7	27,5
972,76	31,8	91,7	93,3	26,8
989,42	29,5	91,7	92,8	26,2
1010,7	27,3	91,7	92,3	25,6
1063,46	27,3	100,0	100,0	27,3
1130,09	25,0	100,0	100,0	26,7
1157,86	22,7	100,0	100,0	26,1
1172,67	20,5	100,0	100,0	25,5
1187,47	18,2	100,0	100,0	25,0
1202,28	15,9	100,0	100,0	24,5
1223,57	13,6	100,0	100,0	24,0
1258,74	11,4	100,0	100,0	23,5
1282,8	9,1	100,0	100,0	23,0
1313,35	6,8	100,0	100,0	22,6
1436,43	4,5	100,0	100,0	22,2
1965,82	2,3	100,0	100,0	21,8
2401,8	0,0	100,0	100,0	21,4

Lampiran 5

CURICULUM VITAE**I. Data Pribadi:**

1. Nama : Wildana
2. NIP : 19760413 200502 2 004
3. Pangkat / Golongan : Penata / III c
4. Jenis Kelamin : Perempuan
5. Agama : Islam
6. Tempat / Tgl lahir : Sengkang / 13 April 1976
7. Alamat : Perumahan Puri Asri, Jl. Puri Asri
IV / Blok B, No. 7-8
8. Institusi : Dinas Kesehatan Kab. Wajo

II. Riwayat Pendidikan:

1. SDN 2 Sengkang, lulus tahun 1989
2. SMPN 1 Sengkang, lulus tahun 1991
3. SMAN 1 Sengkang, lulus tahun 1994
4. Sarjana Kedokteran Fakultas Kedokteran Universitas Hasanuddin Makassar, tahun 1999
5. Profesi Dokter Fakultas Kedokteran Universitas Hasanuddin Makassar, tahun 2002
6. Program Pendidikan Dokter Spesialis Patologi Klinik Fakultas Kedokteran Universitas Hasanuddin Makassar, periode 1 Juli 2008
7. Program Pasca Sarjana Universitas Hasanuddin Makassar, periode 1 Juli 2008

III. Riwayat Pekerjaan:

1. Dokter PTT : Puskesmas Keera Kabupaten Wajo, Sul-Sel,
1 november 2002 – 26 maret 2003
Puskesmas wewangrewu Kabupaten Wajo,
Sul-Sel, 27 maret 2003 – 30 Januari 2004
2. CPNS : Puskesmas Pammana Kabupaten Wajo,
Sul-Sel, 1 Februari 2005 – 30 Maret 2006
3. PNS : Puskesmas Pammana Kabupaten Wajo,
Sul-Sel, 1 April 2006

IV. Karya Ilmiah / Artikel yang telah dipublikasikan:

1. Kejadian Methicillin Resistant Staphylococcus Aureus Di RS. Dr.
Wahidin Sudirohusodo Makassar, Juli 2008 – Juni 2009.
2. Analisis Kadar Hemoglobin pada Pasien HIV-AIDS